Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
Mult Scler Relat Disord
; 45: 102452, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-713197
ABSTRACT
BACKGROUND:
The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding low lymphocyte levels. IMPLICATIONS Benign COVID-19 clinical course and anti-SARS-CoV-2 antibody production can occur in MS patients with lymphopenia, suggesting the possibility to respond to COVID-19 vaccination, once available, in this vulnerable population.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Immunocompromised Host
/
Cladribine
/
Coronavirus Infections
/
Multiple Sclerosis, Relapsing-Remitting
/
Immunosuppressive Agents
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2020
Document Type:
Article
Affiliation country:
J.msard.2020.102452
Similar
MEDLINE
...
LILACS
LIS